We reviewed our research concerning p53 molecules in esophageal squamous cell carcinoma by focusing on the p53 molecular diagnosis and treatment of esophageal squamous cell carcinoma. First, we developed diagnostic tools to analyze serum p53 autoantibodies to detect esophageal squamous cell carcinoma. Positive rate was around 25% to 30% in all patients and around 20% even in stage I patients. Presence of serum p53 antibodies was significantly associated with overexpression of p53 protein in tumor cells. Seropositive patients were more likely than seronegative patients to be resistant to chemotherapy. Monitoring of the titer of serum p53 autoantibodies was useful in predicting patients at high risk of recurrence and/or treatment response. Second, using Ad5CMV-p53 for 10 patients with advanced esophageal squamous cell carcinoma, we carried out a phase I/II study of adenoviralmediated p53 gene therapy. Although no complete response was observed, local tumor was stabilized in nine patients. No serious adverse events related to Ad5CMV-p53 were observed in these patients. One patient survived for over 5 years after the start of p53 gene therapy. Intratumoral injection of Ad5CMV-p53 is therefore safe, feasible, and biologically active when given in multiple doses to patients with esophageal squamous cell carcinoma. Our observations from these clinical studies indicate that p53 is a useful molecular target both in the diagnosis and in the treatment of esophageal squamous cell carcinoma. is reportedly one of the key molecules in the diagnosis and in the treatment of esophageal SCC. 7 The most frequently mutated gene identified in esophageal SCC is the p53 gene, and its mutation and/ or protein overexpression are observed in 40%-60% of patients with esophageal cancer-even in the early phase of carcinogenesis.
Such p53 protein alteration frequently induces p53 autoantibodies (s-p53 Abs) in esophageal SCC. First, we reviewed the clinical significance of s-p53 Abs. Second, we reviewed clinical trials of adenoviral p53 gene therapy for unresectable esophageal SCC. p53 molecular approaches signal the coming of age of esophageal cancer diagnosis and treatment.
| S-P53 ABS IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Alteration and overexpression of p53 protein is reported to induce s-p53 Abs. 13 A strong correlation between the presence of s-p53
Abs, missense gene mutations, and protein accumulation has been observed. 8 The cutoff level-based on the newly developed enzyme-linked immunosorbent assay (ELISA)-was fixed to be 1.3 U/mL. 13 The overall positive rate for s-p53 Abs was 31%, which was significantly higher than that for carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA21-1) (Figure 1 ). 7 The high titer group-unlike the low titer group-showed a significant association with advanced tumor stage and poor prognosis. High s-p53 Abs titer was an independent prognostic factor (P < .001). We found that s-p53 Abs were useful in detecting esophageal cancer and identifying those at high risk of tumor recurrence and poor prognosis. 14 The positive rate of s-p53 Abs in stage I patients was the highest among all serum tumor markers (s-p53 Abs at 23% vs CEA at 11.4%, SCC-Ag at 14.3%, and CYFRA21-1 at 5.7%) (Figure 1) . 15 Several superficial cancers tested s-p53 Abs-positive 15 and
were treated with endoscopic mucosal resection or endoscopic submucosal dissection (ESD) . The majority of cases tested seronegative after treatment. 16 Recently, we experienced a sudden increase of s-p53 Abs in a patient 8 years after surgical treatment for breast cancer without any recurrent signs of cancer. 17 In this case, early esophageal SCC was detected by endoscopic screening. After ESD, s-p53 Abs levels decreased to within normal range ( Figure 2 ). Monitoring of s-p53
Abs can be helpful not only in the early detection of the recurrence of primary-, but also in the development of metachronous carcinoma. This case was the first in which we monitored the changing titers of s-p53 Abs in the early phase of esophageal cancer progression into the lamina propria mucosae until the disappearance of tumor cells.
Clinical impact of s-p53 Abs in surveillance of high-risk patients was reported. 18 Cawley et al detected s-p53 Abs in four patients with Barrett's esophagus, including one with dysplasia that later progressed to adenocarcinoma. They also detected s-p53 Abs in 10 cancer patients (eight squamous and two adenocarcinoma), two of whom (one squamous, one adenocarcinoma) had antibodies before cancer was diagnosed. 
| IMPACT OF POSTOPERATIVE S-P53

ABS TITER AND PERIOPERATIVE CHANGES OF S-P53 ABS
We evaluated the impact of postoperative s-p53 Abs titer and perioperative changes of s-p53 Abs on survival in 110 patients with esophageal SCC. We generally observed a decrease in s-p53 Abs titer after surgery. 21 Among seropositive patients, those who remained seropositive after surgery (n = 28) had a worse prognosis than patients who showed seroconversion (P = .02; Figure 3 ). Among seropositive patients, the non-decreased titer group showed significantly unfavorable survival. Multivariate analysis showed that postoperative s-p53 Abs was an independent risk factor for worse overall survival (P = .03). Perioperative monitoring of s-p53 Abs titers was useful in identifying patients with esophageal cancer at a high risk of tumor recurrence and poor prognosis. Regarding alterations in titer, continuously seropositive patients and/or the nondecreased titer group, even after surgery, showed significantly unfavorable survival (P < .01; Figure 4 ).
| PRESENCE OF S-P5 3 ABS AND TREATMENT RESPONSE TO CHEMOTHERAPY
We also analyzed the clinicopathological factors of 95 patients with recurrent disease to evaluate the clinical impact of s-p53 Abs on the prediction of treatment response. 22 Of those 95 patients, 76
patients, seven patients, and 12 patients received non-surgical treatment, operative intervention, and no treatment, respectively. Of the non-surgical treatment group, 47 patients, 17 patients, and 12 patients received chemoradiotherapy, chemotherapy, and radiotherapy, respectively. We observed an overall clinical response in 26 of the 76 patients (34%). Multivariate analysis suggested that, at the moment of recurrence, the presence of s-p53 Abs was an independent risk factor for poor overall survival (Table 1) . These clinical impacts of s-p53 Abs may reflect tumor chemosensitivity for cisplatin (CDDP). 23 Recently, Yamashita et al 24 confirmed this tendency in patients who received neoadjuvant chemotherapy followed by surgery, and seropositive patients showed poor treatment response and poor relapse-free survival. 
| IMPACT OF S-P53 ABS IN PATIENTS WITH OTHER GASTROENTEROLOGICAL CANCERS
Generally, the genetic alteration of p53 could induce s-p53 Abs in patients with other gastroenterological cancers. We therefore evaluated the clinical significance of s-p53 Abs in patients with various cancers-including gastric cancers, colorectal cancers, and cholangiocarcinoma ( Figure 5 ). [26] [27] [28] The positive rates were 16%, 30%, and 23% in gastric cancer, colorectal cancer, and cholangiocarcinoma, respectively. Because s-p53 Abs tested positive independently for CEA and/or CA19-9, s-p53 Abs could increase the positive rates of detection in the relatively early phases of cancers.
Perioperative monitoring of the titers in patients showed an association with the risk of recurrence; however, a precise evaluation should be carried out in a large series of patients in multi-institutional studies in the future. Interestingly, some of the colorectal cancer patients with very high titers-over 200 IU/mL-showed relatively better survival compared to other patients ( Figure 6 ). 
| PHASE I/II STUD Y OF P53 GENE THERAPY FOR ESOPHAGEAL SQUAMOUS CELL CAR CINOMA
Based on a preclinical study using p53 recombinant adenovirus (Ad5CMV-p53) on human esophageal SCC cell lines (Figure 7) , 29 we conducted a phase I/II study of p53 gene therapy for treatmentresistant esophageal SCC. 30 The primary objective was to determine feasibility and safety of this adenoviral-mediated p53 gene therapy.
The secondary objective was to observe biological responses and anti-tumor effects. Individual doses were 10 9 10 11 to 25 9 10 11 viral particles, depending on tumor size. Ten patients were enrolled in this trial. 28 Before gene therapy, five patients had tumor invasion Overall survival rate with an intent-to-treat analysis was 60% at 1 year (Figure 9 ). Four patients developed clinically diagnosed distant metastases (two bone metastases, one liver and lymph node metastasis, and one lung metastasis). Three of the four patients with development of distant metastases died of their disease within 3 months of the initial viral treatment. Median time to both local and distant progression was 6 months.
| VIRAL SH EDDING AFTER P53
ADENOVIRAL TRANSFE R
We analyzed the presence of adenoviral DNA fragments by DNA-PCR after Ad5CMV-p53 injection. We assessed a total of 220 samples consisting of feces, gargling saliva, urine, and blood plasma. A total of 29.7% of feces samples and 13.2% of gargling saliva samples were positive for adenoviral DNA fragments. After follow up, 89.7% of the positive feces samples and 100% of the positive gargling saliva samples tested negative on day 12 after tumor injection (Figure 10) . 31 Although adenoviral DNA fragments may be pathogenfree for 12 days after injection, patients' feces and gargling saliva still contain adenoviral DNA fragments. Patients treated with 
| NEXT CLINICAL TRIAL OF P53 GENE THERAPY COMBINED WITH CHEMORAD IOTHERAPY
According to recent reports on p53 gene therapy for cancer, Ad5CMV-p53 is frequently used, together with chemotherapy 32, 33 or ionizing radiation. 34, 35 We have also found that Ad5CMV-p53 treatment combined with CDDP or radiation was efficacious for human esophageal SCC, both in vitro and in vivo. F I G U R E 1 0 Summary of Ad-CMV vector biodistribution in three patients with esophageal cancer after Ad5CMV-p53 tumoral injection. 31 Black box, Ad5CMV-p53 positive; crossed box, samples not available; white box, Ad5CMV-p53 negative. Pt, patient
